CMTA Headlines:
The CMTA 35th Anniversary $150,000 Research Challenge Match
When you support the CMTA, you are making a historic difference; you’re touching the lives of 2.8 million patients living with CMT and funding breakthroughs for the next generation! Will you join the 35th Anniversary Matching Challenge?
The 2018 CMTA Report 35th Anniversary Edition
This year the CMTA is celebrating its 35th anniversary. In this special edition of The CMTA Report, go back in time with us and learn about some of the milestones that have shaped the CMTA. We’ve dug into the archives and adapted articles that have appeared in past issues of The CMTA Report. We hope you enjoy seeing how far we’ve come and how it has been you, our partners in the CMT community, that have made all of this progress possible. Read it now …
Progress through Partnerships – Annual Report 2017
The CMTA is pleased to announce the publication of our 2017 Annual Report “Progress Through Partnerships”. Dedicating the past decade to expediting CMT research breakthroughs, the CMTA has made great strides toward treatments and a cure by bringing together researchers, pharmaceutical and biotechnology companies, and patients. Looking back, we believe 2017 stands out as one of the most pivotal years in our journey! Please read the CMTA Annual Report 2017 here.
Regenacy and CMTA Announce Strategic Partnership to Evaluate Ricolinostat, a Selective HDAC6 Inhibitor
The CMTA and Regenacy Pharmaceuticals have announced a collaboration to validate the role of HDAC6 in multiple forms of Charcot-Marie-Tooth (CMT) disease and evaluate the efficacy of ricolinostat, a selective HDAC6 inhibitor, in animal models. The CMTA’s STAR Advisory Board member David Herrmann, M.B.B.Ch., has also joined Regenacy’s Scientific Advisory Board. Learn more…
CMTA Announces Strategic Partnership with Acceleron Pharma to Advance CMT Treatment Options
The CMTA announced a strategic partnership with Acceleron Pharma, a Cambridge-based biopharmaceutical company dedicated to developing medicines to treat serious and rare diseases, including CMT. The CMTA’s Strategy to Accelerate Research (STAR) connects top CMT clinicians and academic researchers with pharmaceutical partners committed to developing treatments, and ultimately, a cure for CMT. Strategic alliances with corporate partners like Acceleron support innovative drug development with a goal to rapidly deliver therapies to CMT patients. Learn more…
The CMTA Leads the Way in Research
For the past decade, the CMTA has led the way in research worldwide with its Strategy To Accelerate Research (STAR). Our mission is to support the development of new drugs to treat CMT, to improve the quality of life for people with CMT, and, ultimately, to find a cure. We thank our community members who have been with us every step of the way! To learn more about STAR, please visit www.cmtausa.org/research/our-star-strategy.
CMT1A Research Breakthrough!
Scientists at Ionis Pharmaceuticals, in collaboration with the Charcot-Marie-Tooth Association, have identified a promising early-stage therapeutic approach with antisense technology for CMT Type 1A (CMT1A), the most common form of the disease, accounting for half of all cases. Read more …
Breakthroughs to a Cure
Studies in two laboratory models of CMT1A not only stopped progression of the disease, but also showed improvement of some symptoms. To deliver the first treatments for CMT1A and other types of CMT, we need funding for clinical trials and further drug development.
What is CMT?
Charcot-Marie-Tooth, or CMT, is the most commonly inherited peripheral neuropathy and affects an estimated 2.8 million people.
Find Your Local Branch
The CMTA has over 80 Branches across North America to support people with CMT, raise awareness, and fund research. Connect with your nearest Branch today!
Fundraise for Our Future
Without fundraising and community volunteers, the CMTA would not be the leading force in CMT Research that it is today. Are you ready to make an impact?
The CMTA’s STAR (Strategy to Accelerate Research)
STAR – Translational Advances
